ILIXADENCEL

UNII:	PY29292DVJ
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	ILIXADENCEL
GSRS Full Record:	PY29292DVJ i

CELL THERAPY CONSISTING OF PRO-INFLAMMATORY MONOCYTE-DERIVED DENDRITIC CELLS (MODCS), ISOLATED FROM AN ALLOGENEIC HUMAN HEALTHY BLOOD DONOR AND EX-VIVOSTIMULATED WITH RESIQUIMOD (R848), POLYINOSINIC-POLYCYTIDYLIC ACID (POLY(I:C)) AND INTERFERON GAMMA (IFN-.GAMMA.). CONTAINS AT LEAST 70% OF DENDRITIC CELLS (DC). THESE CELLS EXPRESS T-LYMPHOCYTE ACTIVATION ANTIGEN CD86 AND THE MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS II MOLECULE HLA-DR, AND SECRETE PRO-INFLAMMATORY SOLUBLE FACTORS, INCLUDING INTERLEUKIN 12 (IL-12) AND C-C MOTIF CHEMOKINE 5 (CCL5; ALSO KNOWN AS RANTES)
Ilixadencel [WHO-DD]
ilixadencel [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

ILIXADENCEL

Synonyms and Mappings

Resources